Insurance Can Decide Survival for Young Cancer Patients
April 2, 2026
Background
Glucagonoma is an uncommon tumor that starts in pancreatic alpha cells. These cells make glucagon, a substance controlling blood sugar. Glucagonoma falls under pancreatic neuroendocrine tumors (PNETs) or islet cell tumors. But it’s a tiny portion of pancreatic tumors, with unclear rates. From pancreatic islets, alpha cells give rise to glucagonomas. They prompt the liver to release glucose, hiking blood sugar. Patients with glucagonoma often show “4Ds”: Diabetes, Dermatitis, Deep vein thrombosis, and Depression. High glucagon causes these symptoms. To diagnose, doctors assess symptoms, use imaging, and check hormone levels. Elevated glucagon indicates glucagonoma.
Epidemiology
Glucagonomas are rare tumors. Their prevalence is thought to be less than one case per twenty million people. That makes getting detailed data on them hard. Their exact incidence is unknown because of how rare they are. Pancreatic neuroendocrine tumors, which include glucagonomas, only make up one to two percent of all pancreatic tumors. Adults are typically when glucagonomas are diagnosed. They often show up in a person’s fifties or sixties. There’s no clear difference between how common they are in men and women. Some cases may be linked to Multiple Endocrine Neoplasia Type 1 (MEN-1), an inherited disorder causing tumors in multiple endocrine glands. But no geographical or ethnic variations in how often they occur have been observed. The symptoms of glucagonomas vary a lot. They can include diabetes, skin rashes, blood clots in veins, and depression. This diversity of symptoms, along with the tumor’s rarity, often leads to delays in diagnosis.
Anatomy
Pathophysiology
Glucagonomas are tumors from pancreatic cells producing too much glucagon hormone. Glucagon raises blood sugar levels. Too much glucagon causes hyperglycemia or high blood sugar. This leads to diabetes mellitus from insulin resistance. People with glucagonomas may get a skin rash called necrolytic migratory erythema. They may lose weight and have malabsorption issues. Glucagonomas increase blood clot risks like deep vein thrombosis. Neurological and psychiatric symptoms like depression can happen. Reasons for these symptoms are not fully understood.
Etiology
Glucagonomas usually happen unexpectedly. Most people who get them don’t have a family history. But some cases link to genetic conditions like MEN-1. That’s where people have a high chance of getting tumors in multiple hormone glands, including the pancreas. Mutations in genes that prevent tumors, like MEN1, may cause glucagonomas. Scientists don’t know the exact reasons glucagonomas develop, though. Genetics or environmental factors play a role. Glucagonomas start when alpha cells in the pancreas grow abnormally. Those cells make glucagon, a hormone. The tumor causes hormone imbalance and problems like high blood sugar and weight loss.
Genetics
Prognostic Factors
Glucagonoma prognosis depends on tumor factors and patient health. The tumor’s stage, or how far it spread, affects outlook – localized tumors fare better than metastatic ones. Size and grade, indicating aggressiveness, are key predictors of outcomes too. Hormone production and treatment response are vital prognostic factors. If the tumor can be surgically removed and the patient is generally healthy, prognosis improves. Specific genetic changes like Multiple Endocrine Neoplasia Type 1 impact disease course and prognosis as well.
Clinical History
Age of Onset:
Physical Examination
Doctors check for glucagonomas in many ways. They look at your skin for rashes around the perineum, buttocks, and lower abdomen. This is called necrolytic migratory erythema. Your weight and nutrition are also checked. Unexplained weight loss is common with glucagonomas. The doctor will feel your abdomen for tenderness, masses, or enlarged organs like the liver or spleen. Your mental health is evaluated for depression or confusion. Skin and nails are inspected for changes related to nutrition deficiencies. The doctor will check for deep vein thrombosis, which is more likely with glucagonomas. Your blood pressure and pulse are measured to assess heart and blood vessel health.
Age group
Associated comorbidity
Glucagonomas usually come with other issues or signs. Those include Multiple Endocrine Neoplasia Type 1 (MEN-1), where tumors grow in many hormone glands. It also includes pancreatitis, which means the pancreas is inflamed. Glucagonomas can cause high blood sugar levels, leading to diabetes mellitus. Signs of a glucagonoma are high blood sugar levels that make you pee a lot, feel very thirsty, and tired. It can also cause a rash called necrolytic migratory erythema on the groin, butt, and lower belly. Weight loss happens because high glucagon levels break down body tissues. A higher risk of blood clots in veins causes swelling, pain, or redness in the affected limb or area. Neurological and mental health issues like depression may occur too.
Associated activity
Acuity of presentation
Glucagonomas have different intensities. Some people feel symptoms slowly. Others experience quick changes. Glucagonomas are uncommon. Their symptoms are vague. Sometimes, diagnosis takes time.
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
Easy-to-read sentences help split the text’s flow. Surgery aims to cure or control a glucagonoma if it’s localized. It removes the tumor if possible. But partial removal might happen if full removal isn’t feasible – to ease symptoms and cut hormone levels. If tumors spread far, targeted drugs like somatostatin analogues help control hormone effects like skin rash, diarrhea. Everolimus, an mTOR inhibitor, treats advanced or metastatic cases when surgery isn’t suitable. Managing diabetes, giving good nutrition, monitoring frequently, offering palliative care aid quality of life, easing symptoms.
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
use-of-a-non-pharmacological-approach-for-treating-glucagonoma
Nutritional Support:
Psychosocial Support:
Physical Activity and Rehabilitation:
Pain Management:
Education and Empowerment:
Complementary and Alternative Therapies:
Symptom Management:
Role of Somatostatin Analogues for the treatment of Glucagonoma
Somatostatin analogues help treat glucagonoma. They control hormone release and ease symptoms. Glucagonomas make too much glucagon. This hormone messes up the body’s normal functions. Our bodies make somatostatin. It controls hormones like glucagon. Man-made somatostatin analogues attach to tumor cells. This includes glucagonoma cells. They cut hormone release from these cells. This action makes blood sugar levels normal. It fixes hyperglycemia from glucagonoma.
Glucagonomas make too much glucagon. Glucagon is a hormone that disturbs normal body actions. Somatostatin controls glucagon and other hormones. Doctors use somatostatin analogues, or man-made hormone-like drugs, to treat glucagonomas. These analogues latch onto tumor cells, including glucagonoma cells. Then they lower glucagon levels, fixing high blood sugar problems caused by excessive glucagon.
Medicine like lanreotide, which works the same way as octreotide, is man-made. They both latch onto special spots in our body, stopping too many hormones from being released by certain tumors. This includes glucagon. Lanreotide comes in short-acting and long-acting forms. Long-acting ones like lanreotide autogel mean you don’t need as many shots.
Role of Everolimus in the treatment of Glucagonoma
Everolimus is in the mTOR inhibitors class. It treats various cancers, including neuroendocrine tumors like glucagonoma. Everolimus works because it stops the mTOR pathway. This pathway is important for cell survival, growth, and increase. In neuroendocrine tumors, including glucagonomas, this pathway doesn’t work right. This causes uncontrolled cell growth and tumor spread. Everolimus stops the mTOR pathway. So it manages neuroendocrine tumor growth and metastasis. It’s approved to treat advanced pancreatic neuroendocrine tumors. This includes tumors linked with syndromes like glucagonoma.
use-of-intervention-with-a-procedure-in-treating-glucagonoma
Doctors use different treatments for glucagonomas. Surgery removes the tumor from the pancreas or lymph nodes. It treats localized glucagonomas. Doctors may cut out metastases too. Embolization blocks blood flow to inoperable tumors. This manages symptoms. Radiofrequency ablation destroys small tumors. It’s used when surgery isn’t possible. Chemoembolization combines chemotherapy drugs and an embolizing agent. It targets tumors that don’t respond to regular chemo. Peptide receptor radionuclide therapy delivers radiation directly to neuroendocrine tumor cells. It may help metastatic glucagonomas with somatostatin receptors.
use-of-phases-in-managing-glucagonoma
Diagnosis:
Initial Treatment:
Ongoing Therapy:
Monitoring and Follow-Up:
Supportive Care:
Palliative Care:
Medication
Future Trends
References
Glucagonoma is an uncommon tumor that starts in pancreatic alpha cells. These cells make glucagon, a substance controlling blood sugar. Glucagonoma falls under pancreatic neuroendocrine tumors (PNETs) or islet cell tumors. But it’s a tiny portion of pancreatic tumors, with unclear rates. From pancreatic islets, alpha cells give rise to glucagonomas. They prompt the liver to release glucose, hiking blood sugar. Patients with glucagonoma often show “4Ds”: Diabetes, Dermatitis, Deep vein thrombosis, and Depression. High glucagon causes these symptoms. To diagnose, doctors assess symptoms, use imaging, and check hormone levels. Elevated glucagon indicates glucagonoma.
Glucagonomas are rare tumors. Their prevalence is thought to be less than one case per twenty million people. That makes getting detailed data on them hard. Their exact incidence is unknown because of how rare they are. Pancreatic neuroendocrine tumors, which include glucagonomas, only make up one to two percent of all pancreatic tumors. Adults are typically when glucagonomas are diagnosed. They often show up in a person’s fifties or sixties. There’s no clear difference between how common they are in men and women. Some cases may be linked to Multiple Endocrine Neoplasia Type 1 (MEN-1), an inherited disorder causing tumors in multiple endocrine glands. But no geographical or ethnic variations in how often they occur have been observed. The symptoms of glucagonomas vary a lot. They can include diabetes, skin rashes, blood clots in veins, and depression. This diversity of symptoms, along with the tumor’s rarity, often leads to delays in diagnosis.
Glucagonomas are tumors from pancreatic cells producing too much glucagon hormone. Glucagon raises blood sugar levels. Too much glucagon causes hyperglycemia or high blood sugar. This leads to diabetes mellitus from insulin resistance. People with glucagonomas may get a skin rash called necrolytic migratory erythema. They may lose weight and have malabsorption issues. Glucagonomas increase blood clot risks like deep vein thrombosis. Neurological and psychiatric symptoms like depression can happen. Reasons for these symptoms are not fully understood.
Glucagonomas usually happen unexpectedly. Most people who get them don’t have a family history. But some cases link to genetic conditions like MEN-1. That’s where people have a high chance of getting tumors in multiple hormone glands, including the pancreas. Mutations in genes that prevent tumors, like MEN1, may cause glucagonomas. Scientists don’t know the exact reasons glucagonomas develop, though. Genetics or environmental factors play a role. Glucagonomas start when alpha cells in the pancreas grow abnormally. Those cells make glucagon, a hormone. The tumor causes hormone imbalance and problems like high blood sugar and weight loss.
Glucagonoma prognosis depends on tumor factors and patient health. The tumor’s stage, or how far it spread, affects outlook – localized tumors fare better than metastatic ones. Size and grade, indicating aggressiveness, are key predictors of outcomes too. Hormone production and treatment response are vital prognostic factors. If the tumor can be surgically removed and the patient is generally healthy, prognosis improves. Specific genetic changes like Multiple Endocrine Neoplasia Type 1 impact disease course and prognosis as well.
Age of Onset:
Doctors check for glucagonomas in many ways. They look at your skin for rashes around the perineum, buttocks, and lower abdomen. This is called necrolytic migratory erythema. Your weight and nutrition are also checked. Unexplained weight loss is common with glucagonomas. The doctor will feel your abdomen for tenderness, masses, or enlarged organs like the liver or spleen. Your mental health is evaluated for depression or confusion. Skin and nails are inspected for changes related to nutrition deficiencies. The doctor will check for deep vein thrombosis, which is more likely with glucagonomas. Your blood pressure and pulse are measured to assess heart and blood vessel health.
Glucagonomas usually come with other issues or signs. Those include Multiple Endocrine Neoplasia Type 1 (MEN-1), where tumors grow in many hormone glands. It also includes pancreatitis, which means the pancreas is inflamed. Glucagonomas can cause high blood sugar levels, leading to diabetes mellitus. Signs of a glucagonoma are high blood sugar levels that make you pee a lot, feel very thirsty, and tired. It can also cause a rash called necrolytic migratory erythema on the groin, butt, and lower belly. Weight loss happens because high glucagon levels break down body tissues. A higher risk of blood clots in veins causes swelling, pain, or redness in the affected limb or area. Neurological and mental health issues like depression may occur too.
Glucagonomas have different intensities. Some people feel symptoms slowly. Others experience quick changes. Glucagonomas are uncommon. Their symptoms are vague. Sometimes, diagnosis takes time.
Easy-to-read sentences help split the text’s flow. Surgery aims to cure or control a glucagonoma if it’s localized. It removes the tumor if possible. But partial removal might happen if full removal isn’t feasible – to ease symptoms and cut hormone levels. If tumors spread far, targeted drugs like somatostatin analogues help control hormone effects like skin rash, diarrhea. Everolimus, an mTOR inhibitor, treats advanced or metastatic cases when surgery isn’t suitable. Managing diabetes, giving good nutrition, monitoring frequently, offering palliative care aid quality of life, easing symptoms.
Nutrition
Pain Management
Nutritional Support:
Psychosocial Support:
Physical Activity and Rehabilitation:
Pain Management:
Education and Empowerment:
Complementary and Alternative Therapies:
Symptom Management:
Endocrinology, Metabolism
Somatostatin analogues help treat glucagonoma. They control hormone release and ease symptoms. Glucagonomas make too much glucagon. This hormone messes up the body’s normal functions. Our bodies make somatostatin. It controls hormones like glucagon. Man-made somatostatin analogues attach to tumor cells. This includes glucagonoma cells. They cut hormone release from these cells. This action makes blood sugar levels normal. It fixes hyperglycemia from glucagonoma.
Glucagonomas make too much glucagon. Glucagon is a hormone that disturbs normal body actions. Somatostatin controls glucagon and other hormones. Doctors use somatostatin analogues, or man-made hormone-like drugs, to treat glucagonomas. These analogues latch onto tumor cells, including glucagonoma cells. Then they lower glucagon levels, fixing high blood sugar problems caused by excessive glucagon.
Medicine like lanreotide, which works the same way as octreotide, is man-made. They both latch onto special spots in our body, stopping too many hormones from being released by certain tumors. This includes glucagon. Lanreotide comes in short-acting and long-acting forms. Long-acting ones like lanreotide autogel mean you don’t need as many shots.
Endocrinology, Metabolism
Everolimus is in the mTOR inhibitors class. It treats various cancers, including neuroendocrine tumors like glucagonoma. Everolimus works because it stops the mTOR pathway. This pathway is important for cell survival, growth, and increase. In neuroendocrine tumors, including glucagonomas, this pathway doesn’t work right. This causes uncontrolled cell growth and tumor spread. Everolimus stops the mTOR pathway. So it manages neuroendocrine tumor growth and metastasis. It’s approved to treat advanced pancreatic neuroendocrine tumors. This includes tumors linked with syndromes like glucagonoma.
Surgery, Surgical Oncology
Doctors use different treatments for glucagonomas. Surgery removes the tumor from the pancreas or lymph nodes. It treats localized glucagonomas. Doctors may cut out metastases too. Embolization blocks blood flow to inoperable tumors. This manages symptoms. Radiofrequency ablation destroys small tumors. It’s used when surgery isn’t possible. Chemoembolization combines chemotherapy drugs and an embolizing agent. It targets tumors that don’t respond to regular chemo. Peptide receptor radionuclide therapy delivers radiation directly to neuroendocrine tumor cells. It may help metastatic glucagonomas with somatostatin receptors.
Surgery, Surgical Oncology
Diagnosis:
Initial Treatment:
Ongoing Therapy:
Monitoring and Follow-Up:
Supportive Care:
Palliative Care:
Glucagonoma is an uncommon tumor that starts in pancreatic alpha cells. These cells make glucagon, a substance controlling blood sugar. Glucagonoma falls under pancreatic neuroendocrine tumors (PNETs) or islet cell tumors. But it’s a tiny portion of pancreatic tumors, with unclear rates. From pancreatic islets, alpha cells give rise to glucagonomas. They prompt the liver to release glucose, hiking blood sugar. Patients with glucagonoma often show “4Ds”: Diabetes, Dermatitis, Deep vein thrombosis, and Depression. High glucagon causes these symptoms. To diagnose, doctors assess symptoms, use imaging, and check hormone levels. Elevated glucagon indicates glucagonoma.
Glucagonomas are rare tumors. Their prevalence is thought to be less than one case per twenty million people. That makes getting detailed data on them hard. Their exact incidence is unknown because of how rare they are. Pancreatic neuroendocrine tumors, which include glucagonomas, only make up one to two percent of all pancreatic tumors. Adults are typically when glucagonomas are diagnosed. They often show up in a person’s fifties or sixties. There’s no clear difference between how common they are in men and women. Some cases may be linked to Multiple Endocrine Neoplasia Type 1 (MEN-1), an inherited disorder causing tumors in multiple endocrine glands. But no geographical or ethnic variations in how often they occur have been observed. The symptoms of glucagonomas vary a lot. They can include diabetes, skin rashes, blood clots in veins, and depression. This diversity of symptoms, along with the tumor’s rarity, often leads to delays in diagnosis.
Glucagonomas are tumors from pancreatic cells producing too much glucagon hormone. Glucagon raises blood sugar levels. Too much glucagon causes hyperglycemia or high blood sugar. This leads to diabetes mellitus from insulin resistance. People with glucagonomas may get a skin rash called necrolytic migratory erythema. They may lose weight and have malabsorption issues. Glucagonomas increase blood clot risks like deep vein thrombosis. Neurological and psychiatric symptoms like depression can happen. Reasons for these symptoms are not fully understood.
Glucagonomas usually happen unexpectedly. Most people who get them don’t have a family history. But some cases link to genetic conditions like MEN-1. That’s where people have a high chance of getting tumors in multiple hormone glands, including the pancreas. Mutations in genes that prevent tumors, like MEN1, may cause glucagonomas. Scientists don’t know the exact reasons glucagonomas develop, though. Genetics or environmental factors play a role. Glucagonomas start when alpha cells in the pancreas grow abnormally. Those cells make glucagon, a hormone. The tumor causes hormone imbalance and problems like high blood sugar and weight loss.
Glucagonoma prognosis depends on tumor factors and patient health. The tumor’s stage, or how far it spread, affects outlook – localized tumors fare better than metastatic ones. Size and grade, indicating aggressiveness, are key predictors of outcomes too. Hormone production and treatment response are vital prognostic factors. If the tumor can be surgically removed and the patient is generally healthy, prognosis improves. Specific genetic changes like Multiple Endocrine Neoplasia Type 1 impact disease course and prognosis as well.
Age of Onset:
Doctors check for glucagonomas in many ways. They look at your skin for rashes around the perineum, buttocks, and lower abdomen. This is called necrolytic migratory erythema. Your weight and nutrition are also checked. Unexplained weight loss is common with glucagonomas. The doctor will feel your abdomen for tenderness, masses, or enlarged organs like the liver or spleen. Your mental health is evaluated for depression or confusion. Skin and nails are inspected for changes related to nutrition deficiencies. The doctor will check for deep vein thrombosis, which is more likely with glucagonomas. Your blood pressure and pulse are measured to assess heart and blood vessel health.
Glucagonomas usually come with other issues or signs. Those include Multiple Endocrine Neoplasia Type 1 (MEN-1), where tumors grow in many hormone glands. It also includes pancreatitis, which means the pancreas is inflamed. Glucagonomas can cause high blood sugar levels, leading to diabetes mellitus. Signs of a glucagonoma are high blood sugar levels that make you pee a lot, feel very thirsty, and tired. It can also cause a rash called necrolytic migratory erythema on the groin, butt, and lower belly. Weight loss happens because high glucagon levels break down body tissues. A higher risk of blood clots in veins causes swelling, pain, or redness in the affected limb or area. Neurological and mental health issues like depression may occur too.
Glucagonomas have different intensities. Some people feel symptoms slowly. Others experience quick changes. Glucagonomas are uncommon. Their symptoms are vague. Sometimes, diagnosis takes time.
Easy-to-read sentences help split the text’s flow. Surgery aims to cure or control a glucagonoma if it’s localized. It removes the tumor if possible. But partial removal might happen if full removal isn’t feasible – to ease symptoms and cut hormone levels. If tumors spread far, targeted drugs like somatostatin analogues help control hormone effects like skin rash, diarrhea. Everolimus, an mTOR inhibitor, treats advanced or metastatic cases when surgery isn’t suitable. Managing diabetes, giving good nutrition, monitoring frequently, offering palliative care aid quality of life, easing symptoms.
Nutrition
Pain Management
Nutritional Support:
Psychosocial Support:
Physical Activity and Rehabilitation:
Pain Management:
Education and Empowerment:
Complementary and Alternative Therapies:
Symptom Management:
Endocrinology, Metabolism
Somatostatin analogues help treat glucagonoma. They control hormone release and ease symptoms. Glucagonomas make too much glucagon. This hormone messes up the body’s normal functions. Our bodies make somatostatin. It controls hormones like glucagon. Man-made somatostatin analogues attach to tumor cells. This includes glucagonoma cells. They cut hormone release from these cells. This action makes blood sugar levels normal. It fixes hyperglycemia from glucagonoma.
Glucagonomas make too much glucagon. Glucagon is a hormone that disturbs normal body actions. Somatostatin controls glucagon and other hormones. Doctors use somatostatin analogues, or man-made hormone-like drugs, to treat glucagonomas. These analogues latch onto tumor cells, including glucagonoma cells. Then they lower glucagon levels, fixing high blood sugar problems caused by excessive glucagon.
Medicine like lanreotide, which works the same way as octreotide, is man-made. They both latch onto special spots in our body, stopping too many hormones from being released by certain tumors. This includes glucagon. Lanreotide comes in short-acting and long-acting forms. Long-acting ones like lanreotide autogel mean you don’t need as many shots.
Endocrinology, Metabolism
Everolimus is in the mTOR inhibitors class. It treats various cancers, including neuroendocrine tumors like glucagonoma. Everolimus works because it stops the mTOR pathway. This pathway is important for cell survival, growth, and increase. In neuroendocrine tumors, including glucagonomas, this pathway doesn’t work right. This causes uncontrolled cell growth and tumor spread. Everolimus stops the mTOR pathway. So it manages neuroendocrine tumor growth and metastasis. It’s approved to treat advanced pancreatic neuroendocrine tumors. This includes tumors linked with syndromes like glucagonoma.
Surgery, Surgical Oncology
Doctors use different treatments for glucagonomas. Surgery removes the tumor from the pancreas or lymph nodes. It treats localized glucagonomas. Doctors may cut out metastases too. Embolization blocks blood flow to inoperable tumors. This manages symptoms. Radiofrequency ablation destroys small tumors. It’s used when surgery isn’t possible. Chemoembolization combines chemotherapy drugs and an embolizing agent. It targets tumors that don’t respond to regular chemo. Peptide receptor radionuclide therapy delivers radiation directly to neuroendocrine tumor cells. It may help metastatic glucagonomas with somatostatin receptors.
Surgery, Surgical Oncology
Diagnosis:
Initial Treatment:
Ongoing Therapy:
Monitoring and Follow-Up:
Supportive Care:
Palliative Care:

Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.

On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.

When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
